# Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

> **NCT05105958** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Zurich** · enrollment: 98 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Tideglusib

## Key facts

- **NCT ID:** NCT05105958
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105958, "Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05105958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*